NICE has given the all clear for fingolimod (Gilenya) - a pill that can help adults suffering from highly active relapsing-remitting multiple sclerosis (RRMS).
Fingolimod is the first pill-based medicine that can help reduce the number of relapses as other treatments are administered by injection.
NICE has recommended using fingolimod on adult patients who, despite taking beta interferons, are showing an unchanged or increased relapse rate or ongoing severe relapses compared to the previous year.
Around 27,500 people in England and Wales are effected by RRMS which is characterised by periods when symptoms worsen and then improve.
Professor Carole Longson, director of the Health Technology Evaluation Centre at NICE said: “Our committee concluded that fingolimod is a valuable new therapy for highly active relapsing-remitting multiple sclerosis.
“Multiple sclerosis can be a disabling condition and so we hope that this novel treatment will help to reduce relapses for these people.”